Ibrutinib plus bortezomib plus R-CHOP for higher-risk DLBCL: Efficacy, feasibility and molecular predictors

被引：0

作者：

Denker, S. ^{[1
,2
]}

Bittner, A. ^{[1
,2
]}

Frick, M. ^{[1
]}

Kase, J. ^{[1
]}

Hoffmann, J. ^{[3
]}

Trenker, C. ^{[3
]}

Keller, U. ^{[2
,4
,5
,6
,7
]}

Bogner, C. ^{[8
]}

Huttmann, A. ^{[9
]}

Duhrig, J. ^{[9
]}

Janz, M. ^{[4
,7
]}

Mathas, S. ^{[4
,7
]}

Marks, R. ^{[10
,11
]}

Krohn, U. ^{[10
,11
]}

Bhattacharya, A. ^{[4
]}

Na, I. -K ^{[1
,2
]}

Gebauer, B. ^{[4
]}

Savic, L. J. ^{[4
]}

Hubner, N. ^{[7
]}

Akalin, A. ^{[12
]}

Eils, R. ^{[2
]}

Bullinger, L. ^{[1
,2
,5
,6
]}

Schmitt, C. A. ^{[1
,7
,13
]}

机构：

[1] Charite Univ Med Berlin, Med Klin mS Hamatol Onkol & Tumorimmunol, Campus Virchow Klinikum, Berlin, Germany

[2] Berlin Inst Hlth BIH, Berlin, Germany

[3] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol, Oncol,Immunol, Marburg, Germany

[4] Charite Univ Med Berlin, Berlin, Germany

[5] German Canc Res Ctr, Heidelberg, Germany

[6] German Canc Consortium DKTK, Heidelberg, Germany

[7] Max Delbruck Ctr Mol Med, Berlin, Germany

[8] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany

[9] Univ Duisburg Essen, Univ Klinikum Essen, Klin Hamatol, Essen, Germany

[10] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Fac Med, Freiburg, Germany

[11] Univ Freiburg, Dept Hematol Oncol Stem Cell Transplantat, Med Ctr, Freiburg, Germany

[12] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Bioinformat & Omics Data Sci Platform, Berlin, Germany

[13] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V104

引用

页码：24 / 24

页数：1

共 50 条

[11] CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
Ayed O. Ayed
Annalisa Chiappella
Levi Pederson
Betsy R. Laplant
Angela Giovanna Congiu
Gianluca Gaidano
Michele Spina
Alessandro Re
Federica Cavallo
Gerardo Musuraca
William R. Macon
Thomas Witzig
Umberto Vitolo
Grzegorz S. Nowakowski
Blood Cancer Journal, 8
[12] A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).
Tilly, Herve
Flowers, Christopher
Friedberg, Jonathan W.
Herbaux, Charles
Morschhauser, Franck
Sehn, Laurie Helen
Sharman, Jeff Porter
Trneny, Marek
Wang, Lijia
Lee, Calvin
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[13] CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
Ayed, Ayed O.
Chiappella, Annalisa
Pederson, Levi
Laplant, Betsy R.
Congiu, Angela Giovanna
Gaidano, Gianluca
Spina, Michele
Re, Alessandro
Cavallo, Federica
Musuraca, Gerardo
Macon, William R.
Witzig, Thomas
Vitolo, Umberto
Nowakowski, Grzegorz S.
BLOOD CANCER JOURNAL, 2018, 8
[14] Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup
Jiang, Shiyu
Qin, Yan
Jiang, Hongxin
Liu, Biao
Shi, Jianming
Meng, Fanlu
Liu, Peng
Yang, Jianliang
Yang, Sheng
He, Xiaohui
Zhou, Shengyu
Gui, Lin
Liu, Hao
Lin, Jing
Han Han-Zhang
Shi, Yuankai
INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (09) : 2611 - 2620
[15] Phase 1 Trial of Bortezomib Plus R-CHOP in Previously Untreated Patients With Aggressive Non-Hodgkin Lymphoma
Furman, Richard R.
Martin, Peter
Ruan, Jia
Cheung, Ying-Kuen K.
Vose, Julie M.
LaCasce, Ann S.
Elstrom, Rebecca
Coleman, Morton
Leonard, John P.
CANCER, 2010, 116 (23) : 5432 - 5439
[16] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results
Flowers, C.
Sinha, R.
Kaufman, J.
Shenoy, P.
Lewis, C.
Bumpers, K.
Rogatko, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[17] REAL-TIME CELL-OF-ORIGIN SUBTYPE IDENTIFICATION BY GENE EXPRESSION PROFILE IN THE PHASE 3 ROBUST TRIAL OF LENALIDOMIDE plus R-CHOP VS PLACEBO plus R-CHOP IN PREVIOUSLY UNTREATED ABC-TYPE DLBCL
Vitolo, U.
Chiappella, A.
Witzig, T. E.
Spina, M.
Gascoyne, R. D.
Zhang, L.
Flament, J.
Repici, J.
Conlin, E.
Delissio, K.
Nowakowski, G. S.
HAEMATOLOGICA, 2016, 101 : 392 - 392
[18] Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study
Hawkes, Eliza A.
Chong, Geoffrey
Smith, Charmaine
Lee, Sze-Ting
Churilov, Leonid
McKendrick, Joseph
Renwick, William
Blombery, Piers
Nelson, Niles Elizabeth
Fancourt, Tineke
Hawking, Joanne
Lin, Wendi
Scott, Andrew M.
Barraclough, Allison
Wight, Joel
Grigg, Andrew
Keane, Colm
Fong, Chun Yew
Manos, Kate
BLOOD, 2020, 136
[19] Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
Martin, Peter
Bartlett, Nancy L.
Chavez, Julio C.
Reagan, John L.
Smith, Sonali M.
LaCasce, Ann S.
Jones, Jeffrey
Drew, James
Wu, Chengqing
Mulvey, Erin
Revuelta, Maria, V
Cerchietti, Leandro
Leonard, John P.
BLOOD, 2022, 139 (08) : 1147 - 1159
[20] Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
Nastoupil, Loretta J.
Hess, Georg
Pavlovsky, Miguel A.
Danielewicz, Iwona
Freeman, Jane
Garcia-Sancho, Alejandro Martin
Glazunova, Valeria
Grigg, Andrew
Hou, Jing-Zhou
Janssens, Ann
Kim, Seok Jin
Masliak, Zvenyslava
Mckay, Pam
Merli, Francesco
Munakata, Wataru
Nagai, Hirokazu
Ozcan, Muhit
Preis, Meir
Wang, Tingyu
Rowe, Melissa
Tamegnon, Monelle
Cir, Rui
Henninger, Todd
Curtis, Madeliene
Caces, Donne Bennett
Thieblemont, Catherine
Salles, Gilles
BLOOD ADVANCES, 2023, 7 (22) : 7141 - 7150

← 1 2 3 4 5 →